In the BioHarmony Drug Report Database

"Preview" Icon

Acrivastine

Semprex-d (acrivastine) is a small molecule pharmaceutical. Acrivastine was first approved as Semprex-d on 1994-03-25. It is used to treat allergic rhinitis perennial and urticaria in the USA.

 

Trade Name

 

Semprex-d
 

Common Name

 

acrivastine
 

ChEMBL ID

 

CHEMBL1224
 

Indication

 

allergic rhinitis perennial, urticaria
 

Drug Class

 

Antihistaminics (histamine-H1 receptor antagonists)

Image (chem structure or protein)

Acrivastine structure rendering